These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15795559)

  • 21. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.
    Yasmin S; Jayaprakash V
    Eur J Med Chem; 2017 Jan; 126():879-893. PubMed ID: 27988463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
    Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
    J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
    Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
    J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring.
    Mohammed Iqbal AK; Khan AY; Kalashetti MB; Belavagi NS; Gong YD; Khazi IA
    Eur J Med Chem; 2012 Jul; 53():308-15. PubMed ID: 22575535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homocysteine competes for the peroxisome proliferator-activated receptor nuclear receptors.
    Hayden MR
    J Cardiometab Syndr; 2008; 3(1):70-1. PubMed ID: 18326982
    [No Abstract]   [Full Text] [Related]  

  • 27. Beneficial health effects of Chios Gum Mastic and peroxisome proliferator-activated receptors: indications of common mechanisms.
    Georgiadis I; Karatzas T; Korou LM; Katsilambros N; Perrea D
    J Med Food; 2015 Jan; 18(1):1-10. PubMed ID: 25133901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors.
    Strakova N; Ehrmann J; Bartos J; Malikova J; Dolezel J; Kolar Z
    Neoplasma; 2005; 52(2):126-36. PubMed ID: 15800711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing the progression of diabetes mellitus.
    Reamy BV
    Am Fam Physician; 2005 Feb; 71(3):425. PubMed ID: 15712615
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of medications for the management of patients with NAFLD.
    Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
    Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 33. 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility.
    Henke BR
    Prog Med Chem; 2004; 42():1-53. PubMed ID: 15003718
    [No Abstract]   [Full Text] [Related]  

  • 34. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
    Thiemermann C
    Br J Pharmacol; 2004 Jul; 142(6):1049-51. PubMed ID: 15303252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPAR agonists, - Could tissue targeting pave the way?
    Bugge A; Holst D
    Biochimie; 2017 May; 136():100-104. PubMed ID: 27916640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship.
    Naim MJ; Alam MJ; Ahmad S; Nawaz F; Shrivastava N; Sahu M; Alam O
    Eur J Med Chem; 2017 Mar; 129():218-250. PubMed ID: 28231521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptors ligands, oxidative stress, and cardiac fibroblast extracellular matrix turnover.
    Villarreal FJ; Asbun J
    Hypertension; 2004 Nov; 44(5):621-2. PubMed ID: 15381678
    [No Abstract]   [Full Text] [Related]  

  • 38. Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
    Niino M
    Mini Rev Med Chem; 2007 Nov; 7(11):1129-35. PubMed ID: 18045216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta.
    Huang Y; Zhang H; Shao Z; O'Hara KA; Kopilas MA; Yu L; Netticadan T; Anderson HD
    Cardiovasc Res; 2011 May; 90(2):267-75. PubMed ID: 21183507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pioglitazone].
    Aso Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():620-6. PubMed ID: 22768588
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.